Last reviewed · How we verify
Antifibrinolytic treatment
Antifibrinolytic agents inhibit plasminogen activators and plasmin.
Antifibrinolytic agents inhibit plasminogen activators and plasmin. Used for Treatment of bleeding in patients with hemophilia A or B, Prevention of excessive bleeding during and following surgery.
At a glance
| Generic name | Antifibrinolytic treatment |
|---|---|
| Sponsor | Bayer |
| Drug class | Antifibrinolytic |
| Target | Plasminogen activators and plasmin |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
They work by blocking the conversion of plasminogen to plasmin, which is involved in the breakdown of fibrin clots.
Approved indications
- Treatment of bleeding in patients with hemophilia A or B
- Prevention of excessive bleeding during and following surgery
Common side effects
- Hypersensitivity reactions
- Thrombosis
Key clinical trials
- Clinical Spectrum and Management of Von Willebrand Disease Among Children in Assiut Governorate
- TRial to EvaluAte Tranexamic Acid Therapy in Thrombocytopenia (PHASE3)
- Venous Thromboembolism in Myotonic Dystrophy Type 1 (NA)
- Enhanced Recovery After Surgery in Orthopaedic Spine Surgery (PHASE2, PHASE3)
- COmbined pLaTelet and eRythrocyte AutotransfusioN During Cardiac surgEry (COLTRANE) Trial (NA)
- Study of Different Interventions to Reduce Bruising Following CCH-Aaes Treatment for Cellulite of the Buttocks (PHASE2)
- TXA in Spinal Fusion (PHASE2)
- Effect of Tranexamic Acid on Intraoperative Blood Loss in Patients Undergoing Aquablation (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Antifibrinolytic treatment CI brief — competitive landscape report
- Antifibrinolytic treatment updates RSS · CI watch RSS
- Bayer portfolio CI